Viewing Study NCT01138202

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:57 AM
Ignite Modification Date: 2026-01-29 @ 3:59 AM
Study NCT ID: NCT01138202
Status: COMPLETED
Last Update Posted: 2020-07-17
First Post: 2010-06-04
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HIV Infections View
None Tuberculosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pharmacokinetics View
None safety View
None efficacy View
None Lopinavir/ritonavir View
None HIV/TB View
None rifampicin containing anti-tuberculosis therapy View
None Pharmacokinetics and safety of Lopinavir/ritonavir with rifampicin containing anti-tuberculosis therapy View